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Abstract (250 words) 
IgE sensitization tests, such as skin prick testing and serum specific IgE, have been used to 
diagnose IgE-mediated clinical allergy for many years. Their prime drawback is that they 
detect sensitization which is only loosely related to clinical allergy. Many patients therefore 
require provocation tests to make a definitive diagnosis; these are often expensive and 
potentially associated with severe reactions. The likelihood of clinical allergy can be semi-
quantified from an IgE sensitization test results. This relationship varies though according to 
the patients’ age, ethnicity, nature of the putative allergic reaction and co-existing clinical 
diseases such as eczema. The likelihood of clinical allergy can be more precisely estimated 
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from an IgE sensitization test result, by taking into account the patient’s presenting features 
(pre-test probability). The presence of each of these patient specific factors may mean that a 
patient is more or less likely to have clinically allergy with a given test result (post-test 
probability). We present two approaches to including pre-test probabilities in the 
interpretation of results. These approaches are currently limited by a lack of data to allow us 
to derive pre-test probabilities for diverse setting, regions and allergens. Also, co-factors, 
such as exercise, may be necessary for exposure to an allergen to result in an allergic 
reaction in specific IgE positive patients.  The diagnosis of IgE-mediated allergy is now being 
aided by the introduction of allergen component testing which may identify clinically relevant 
sensitization. Other approaches are in development with basophil activation testing being 
closest to clinical application. 
 
Introduction  
Allergies are the most frequent chronic diseases in Europe today, affecting the daily lives of 
more than 60 million people (1). Typical manifestations are asthma, rhinitis, eczema, food 
allergy and anaphylaxis. Many non-allergic disorders present with symptoms that are similar 
to allergic diseases making it important to have good tests for allergy. There are also many 
situations where a patient may be exposed to more than one putative allergen, so tests to 
identify the triggering allergen are required. Allergic diseases can be divided into IgE 
mediated and non-IgE mediated allergy (2). IgE mediated allergy, with rapid onset of 
symptoms after exposure to the allergen, is associated with specific IgE to the relevant 
allergen.  This report will focus on IgE-mediated allergy as we have a number of routine 
clinical tests that can detect the presence of specific IgE. Skin prick testing (SPT) can 
provide immediate information about the presence of IgE sensitization to specific allergens in 
clinic (3). Serum specific IgE testing requires blood to be sent to a laboratory and can be 
tested to allergen extracts or individual allergen components (4). Atopy patch testing has 
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been developed over the last decade to understand the relationship between IgE 
sensitization and the cell-mediated response that characterizes atopic eczema but is not 
widely used (5). Other approaches to testing for IgE-mediated allergy, such as basophil 
activation test, have been used in the research setting and their application for clinical use is 
in development (6). The drawback of IgE sensitization tests is that they report the presence 
of specific IgE, not the presence of clinical allergy (Figure 1). However, when used by 
clinicians trained in their interpretation, they are useful to support a diagnosis of clinical 
allergy and identify the likely triggering allergens within the context of a full clinical history.  
There have been considerable advances in allergy over the last decade. Firstly, we now 
have a better understanding of the pathophysiology of allergic disease and immunological 
impact of therapies. Secondly, technological advances have allowed us to detect individual 
allergen components. Finally, with better datasets, we are beginning to understand the 
relationship between specific presentations, IgE sensitization test results and clinical allergy. 
For these reasons, the European Academy of Allergy and Clinical Immunology (EAACI) 
formed a Task Force to reassess how we employ IgE sensitization tests. The Task Force 
involved a wide range of clinicians, scientists and patient groups. The aim of the Task Force 
was to refine our conceptual approach to interpreting IgE test results by integrating 
information from the patient history with the test results and to consider additional tests to 
improve our ability to accurately diagnose clinical allergy to allow us to improve patient care. 
Although many of the examples used are from food allergy, given that we have much better 
evidence in this area, the approach is a generic one that should be applicable to any allergic 
disease. This position paper builds on the activities of other EAACI diagnostic task forces 
including those focused on children (7), rhinitis (8) and food allergy (9, 10). While this 
position paper is primarily aimed at allergists, the Task Force is planning to disseminate the 
concepts more widely using focused materials aimed at different audiences including 
specialty physicians, primary care doctors and patients. 
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The relevance of IgE sensitization to clinical allergy  
Pathophysiology of IgE-mediated allergy 
An understanding of the pathophysiology of IgE-mediated allergy is useful for considering 
how to best interpret allergy test results. Mast cell degranulation commences with cross-
linking of IgE receptors by allergen, functional autoantibodies against IgE or the high affinity 
IgE receptor (FcεRI), or FcεRI-independent such as opiates or C5a complement. This results 
in calcium-dependent series of intracellular signalling events causing a piecemeal or 
anaphylactic degranulation of tissue mast cells and circulating basophils. Preformed 
mediators, such as histamine and the generation of vasoactive eicosanoids, induce an acute 
cellular inflammatory response. Longterm effects on inflammation are influenced by local 
tissue factors and structures. 
The immediate effects of histamine release depend on the organ affected (Box 1). They 
include itching, redness, weals and angio-oedema of the skin; wheezing of the lung; 
rhinorrhoea, nasal blockage and sneezing; lacrimation and itching of the eye; vomiting, 
diarrhoea and abdominal pain of the bowel and faintness and tachycardia of the circulation, 
culminating in collapse if the reaction is severe. Understanding how organs are affected 
differently by the same downstream stimulus-secretion events in the mast cell and basophil 
resulting in allergic disease and how IgE-induced hypersensitivity may be abrogated by the 
development of immunological tolerance is central to understanding allergy. 
Development of tolerance in IgE-mediated allergy 
The development of natural tolerance is complex and poorly understood but the events 
involved in specific allergen immunotherapy have been closely studied (11). They involve the 
induction of peripheral T-cell tolerance by promotion of regulatory Treg and Tr1 cells. These 
directly or indirectly suppress pro-inflammatory cells including eosinophils, mast cells and 
basophils by formation of specific IgG4, followed by reduction in specific IgE.  
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Diagnosis of IgE sensitization in clinical practice 
The spectrum of clinical disease linked with IgE-sensitisation includes anaphylaxis, asthma, 
atopic dermatitis, conjunctivitis, drug reactions, eosinophilic enteritis, food allergies, oral 
allergy syndrome, rhinitis, urticaria and venom allergy (examples in Box 1). The primary tool 
for assessing immediate hypersensitivity reactions is the history. Investigations are, to some 
extent, disease specific (Table 1). They include skin prick testing (SPT) with whole allergen 
extracts, prick-to-prick testing with fresh fruits/vegetables, atopy patch testing and serum 
specific IgE for whole allergen extracts and component resolved diagnostic testing. 
Challenges may be undertaken in an appropriate clinical context.  
Careful history taking is essential for targeted specific IgE testing. It is recommended that 
SPT for anaphylaxis, especially to foods and drugs, should be performed with facilities 
available for resuscitation because severe systemic allergic reactions and rare deaths have 
occurred (12). Multifactorial anaphylaxis due to co-factors may involve challenge with the 
suspected triggers concurrently if allergen testing is negative. Testing for specific IgE to 
omega-5 gliadin in cereal grain may be relevant to patients with a history of exercise-induced 
anaphylaxis or tropomysin in patients with house dust mite sensitization.  
 
The relevance of patient and environmental factors in interpreting IgE sensitization 
test results  
Personal, family and medical features of a patient's history are the paramount considerations 
in determining when to test for allergic sensitization because these factors contribute 
significantly to the ability of the clinician to correctly interpret these tests. 
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Personal factors 
It is well known from both clinic- and population-based studies that the prevalence of the 
disease in a population strongly influences the usefulness of the disease-specific tests. 
Screening of non-symptomatic individuals with specific IgE tests has a low positive predictive 
value, in the range of 50%. In clinic populations, where the likelihood of the disease being 
present is higher, the positive predictive value of skin prick testing (SPT) or specific IgE 
testing may be higher than 85% (13). In contrast, in both unselected and referred 
populations the tests have high negative predictive value and specificity.  
Individuals from different ethnic backgrounds may have different tendencies to develop or 
demonstrate positive skin test and specific IgE results. This has been shown recently in the 
screening data from the LEAP study where higher rates of specific IgE were found in black 
individuals than in other ethnic groups (14). Also specific IgE levels for peanut are higher in 
African-American subjects than in non-African-American subjects in US studies (15). 
It has been extensively documented that a subject’s age has a considerable impact on the 
interpretation of tests, for example, a difference of a year may double the likelihood of clinical 
allergy in pre-school children (16)  
Other patient factors include the presence or absence of associated diseases such as atopic 
dermatitis/eczema. There is a strong association between eczema severity and food allergy 
(14, 17); this may relate to underlying filaggrin mutations (18). 
 
Environmental factors 
Geographical location of patients may make considerable differences. Important factors are 
presumably temperature, humidity and pollen exposure. In Australia, rates of peanut allergy 
are higher in the South than the North (19) and specific IgE testing for peanut shows 
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different patterns from North and Western to Southern Europe (20,21); Ara h 2 is the 
dominant allergen in the North and West, but being of less significance in Southern Europe 
(22). Similarly, the EPAAC study showed wide variations in peanut specific IgE levels across 
European countries in a pre-school population with moderately severe eczema (23).  
 
Other factors 
Potential co-factors also need to be considered when interpreting the clinical history in 
relation to IgE test results. Exercise in the few hours after eating a specific food to which the 
individual is sensitized might be necessary in order to trigger a food-related reaction (24). 
Other cofactors include physical and emotional stress, infections and medications. Co-
existing morbidities such as mastocytosis in beekeepers can definitely modify the pattern of 
reaction and may influence IgE testing interpretation (25). 
Finally, IgE testing may also be used for the follow-up of an allergic disease. Changes in 
results with sequential testing in individual patients can indicate whether food allergies are 
likely to persist or resolve (26, 27). They can be used to decide if repeat food challenge is 
needed for assessing if a child has outgrown a specific food (28). 
 
Maximizing the available diagnostic information by treating SPT and specific IgE 
results as continuous measures  
Traditionally, skin prick testing and specific IgE results have been dichotomised into positive 
or negative according to an arbitrary cut off value.  Typically, this was a 3mm wheal diameter 
for skin prick testing and 0.35 kU/l for specific IgE.  This has given rise to the use of 
sensitivity (proportion of true positives that are correctly identified) and specificity (proportion 
of true negatives that are correctly identified) as a way of describing the utility of the test 
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(10).  There is a trade-off in terms of how useful tests are, those with good sensitivity usually 
have poor specificity and visa versa. Sensitivity and specificity provide a population 
perspective, while this may be useful for public health screening tests, it is less helpful for 
interpreting test results for individual patients. So a patient with a SPT ≥3mm or specific IgE 
of ≥0.35kU/L to a food, only has an approximate 50% chance of being allergic; meanwhile 
another patient with a 0mm SPT or <0.35 specific IgE result still has approximately a 10% 
chance of being allergic to that food.   
The introduction of 95% positive predictive values (29) has helped clinicians to provide more 
clinically relevant recommendations from the test results.  An example would be 15kU/L for 
peanut, children with a result at or above this value have a 95% chance of having peanut 
allergy (30), there are many others examples in the literature (3). This approach provides a 
patient rather than a population perspective. However, most patients have results that fall 
into the grey area below the 95% positive predictive value (29) (Figure 2), the confidence 
intervals associated with these positive predictive values are wide so they are not as precise 
as they may seem to be (31) and they do not take into account other factors such as 
presenting history.  
 
In a further refinement of the interpretation of allergy test results, the relationship between 
the result and the probability of clinical allergy has been modelled using logistic regression. 
This approach gives curves where the probability of clinical allergy can be estimated for 
different test results (32, 30) (Figure 3). While this appears to maximise the information 
available to guide clinical management, these probability curves only relate to the 
relationship between test result and clinical allergy in an “average” patient.  Patients seen in 
an allergy clinic are very heterogeneous, for example, some may have a non-allergic 
underlying disorder and others may be sensitized but not clinically allergic.   
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Many groups have looked to see whether IgE test results can provide information about the 
likely severity of future allergic reactions. In general, no relationship has been found (32) 
although one study found a weak relationship with more severe reactions being associated 
with slightly larger SPT results (33).  
Utilizing allergen components to improve our diagnostic approach  
Traditional diagnostic tests in allergy are directed towards crude extracts which are made up 
of a number of different allergenic molecules. These different molecules can be individually 
assayed using component-resolved diagnostics (CRD) (34). CRD can discriminate between 
binding to potent, more relevant allergens and cross-reactive, clinically less relevant 
allergens. In allergen extracts some allergens are present in a sub-optimal concentration. 
Allergen extracts contain, in addition to the allergens, many other non-allergenic components 
that might hamper the analysis of IgE binding to the relevant allergens, the CRD approach 
avoids this issue.   
CRD has introduced improvements in allergy diagnostics, especially in the areas of 
respiratory (35) and food allergies. For instance, more than 10 different allergenic peanut 
proteins are described: Ara h 1 to Ara h 13. Within this group it seems that IgE binding to Ara 
h 2 and Ara h 6 allergens, belonging to the conglutin protein family, arethe most relevant to 
clinical peanut allergy (36). The Ara h 8 allergen in peanut belongs to the PR-10 family, like 
Bet v 1 the major allergen in birch pollen. This can cause false positive test results when 
patients with birch pollen allergy are tested with whole peanut extract. Additionally, some of 
the allergens in food can predict severe type of reactions. This has been shown for apple 
where Mal d 1-specific IgE is associated with mild, local allergic reactions, while Mal d 3-
specific IgE is associated with more severe, systemic reactions. Also in hazelnut allergy, Cor 
a 1 is associated with mild while Cor a 9 and Cor a 14 are associated with more severe 
allergic reactions (37, 38). 
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CRD can also be used to define the most relevant allergen for allergy immunotherapy. For 
instance, in the case of insect venom allergy with clinical non-relevant cross-reactivity 
between bee and wasp allergens, the determination of IgE to the bee venom protein Api m 1 
and wasp venom allergens Ves v 1 and Ves v 5 can be helpful in determining the clinically 
relevant sensitization (39).  
In a diagnostic setting there are a number of ways that CRD can be utilised. The most widely 
used approach is determination as single component-specific-IgE (e.g. ImmunoCAP, 
ImmuLite, HyTech) (40). Single determination can also be performed by the basophil 
activation test, although the latter is less available in routine settings. To fully utilise the 
potential of CRD, a number of IgE components need to be assayed per patient in a multiplex 
analysis. This can be done in a multiplex system, currently available as the semi-quantitive 
ImmunoCAP-ISAC system which enables the determination of IgE binding to 112 allergens 
in one test run using only 30 microlitres of serum.   An important difference between single 
and multiplex systems is the amount of allergen, the ISAC system uses approximately 100 
000 fold less allergen than the ImmunoCAP (40, 41). This may underlie its lower sensitivity 
at low sIgE levels as there will be more competition between allergen specific IgG and IgE to 
bind to the lower amount of immobilized allergen on the ISAC chip (40). Also the allergens 
coupled to the single allergen system are not always the same as on the multiplex system 
and allergens will differ between manufacturers.   
The multiplex analysis approach generates multiple data points per patient, this has 
important implications for how these data are interpreted. Results for 112 individual allergens 
might be too complicated to interpret with many clinically irrelevant sensitizations. An 
approach where the focus is on IgE binding to specific groups of allergens maybe more 
helpful and diagnostic algorithms are currently being developed to do this.   
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Potential for IgG to confound the result of sIgE assay systems  
The level of specific IgE may be underestimated by the presence of other allergen-specific 
antibodies, particularly by specific IgG’s including IgG4. It is also likely that allergen-blocking 
antibodies mitigate the clinical effects of specific IgE (42). For this reason, it has been 
argued that susceptibility to interference makes the outcome of a specific IgE test clinically 
more relevant. However, such interference by allergen-blocking antibodies is undesirable 
from the analytical point of view, because the outcome of the assay is not accurately 
reflecting the level of specific IgE in the sample. With high levels of allergen in the testing 
system (eg UniCAP system) interference by allergen-blocking antibody is unlikely. Where 
allergen levels are lower (eg ISAC), the risk of interference increases (43). This may 
particularly important following specific immunotherapy where specific IgG levels are 
elevated.  
 
Integrating patient, environmental and allergen factors with IgE test results to predict 
the likelihood of clinical allergy 
Probability curves provide an estimate of the risk of clinical allergy for specific IgE test 
results (Figure 3) for the “average” patient. The chance of clinical allergy can though be 
more precisely estimated from a test result by taking into account the presenting features of 
a patient; this is the so-called pre-test probability (44, 9).  A nomogram approach to 
interpreting test results in relationship to the pre-test probability has been developed (45).  
This calculates the chance of clinical allergy using a likelihood ratio which is the likelihood of 
a given test result in clinically allergic subject over the likelihood of a similar result in normal 
subject (see example in Figure 4).  Although this approach maximised the available clinical 
information, it has not been widely adopted by clinicians, perhaps because it is too time 
consuming, too complicated or clinicians do not have good estimates for pre-test 
probabilities.  There are likelihood ratio data for a limited number of foods (46) and almost no 
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data for aeroallergens.  A problem with many of the studies in which likelihood ratios (or 
other diagnostic parameters) are calculated is that subjects with very different pre-test 
probabilities are mixed (47).   Additionally we do not know if pre-test probabilities are stable 
across different populations.   
 
An alternative approach would be to use modern computer power to generate programmable 
calculator systems to synthesise presenting features together with the allergy test results to 
give a prognostic indication of the likelihood of clinical allergy.  These are underpinned by 
logistic regression models built from clinical cases.  An example is the Cork / Southampton 
prognostic model for food allergy (48).  A proto algorithm was generated using data from 
Southampton food challenges (n=429, peanut, egg, milk).  It was then retrospectively 
applied, evaluated and modified using data from Cork food challenges (n=289, peanut, egg, 
milk).  Finally it was prospectively validated in a blinded study in a further group of Cork 
children undergoing food challenges (n=70, peanut, egg, milk).  The clinical features that 
were found to predict clinical allergy were symptoms, sex, age, skin prick test, specific IgE 
and total IgE.  The model had 97% accuracy for allergy and 94% for tolerance with an area 
under the curve of 0.97 for peanut, 0.95 for egg and 0.94 for milk in the prospective 
validation study.  The model has since been validated in other settings (49).  
The major drawback of the both the nomogram and calculator approach is the need to be 
able to derive a pre-test probability for individual patients. While these have been developed 
for specific settings (48), we do not know how they differ between different setting and 
regions (49). Without a good estimate of the pre-test probability, the predictive power of the 
system will be poor. Further data from a diverse range of setting, regions and allergens is 
required before this approach can be used routinely. It does though show promise.  
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IgE sensitization test results from the patient perspective  
Patients generally regard IgE sensitization tests as allergy tests and they directly self-
translate results into clinical diagnoses. To help patients understand the meaning of their IgE 
sensitization test results, clinicians need to explain the nature of these tests before ordering 
them and not refer to them as allergy tests. Such a clear understanding is essential if 
patients are going to have the confidence to implement changes to their self-management 
plans. On the face of it, a negative IgE sensitization test result might be expected to exclude 
clinical allergy. Patients need to understand that these tests can not completely exclude 
allergy, especially when their clinical history is very suggestive of a clinical allergy. This 
situation needs to be managed with the patient, for example would it be safe to re-introduce 
the food at home in a graded manner or should a food challenge be ordered? Patients need 
to understand that sometimes tests give inconclusive results that do not allow clinicians to 
rule out or rule in clinical allergy. This situation would warrant a discussion about the merits 
of a provocation challenge to establish a firm conclusion. Finally, even where the IgE 
sensitization test is positive, a dialogue with the patient is needed as not all will have results 
that are overwhelming predictive of clinical allergy. Is the level of certainty sufficient for an 
individual patient to be happy to avoid the allergen or is a provocation challenge required to 
firmly establish the diagnosis? Individual patients may have different preferences about 
which IgE sensitization test is used and how they are subsequently managed in the context 
of different test results.  
 
Potential new advances in allergy diagnostics  
Novel approaches to the diagnosis of IgE-mediated allergic disease have been researched 
in the recent years, including the basophil activation test (BAT), IgE and IgG4 binding to 
linear allergen peptides, mediator release and genetic profiling.  
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BAT is a flow cytometry-based assay that assesses changes in the expression of activation 
markers on the surface of basophils following allergen-stimulation (51). Being a functional 
assay, it has the potential to more closely resemble the clinical phenotype of patients than 
methods that merely detect the presence of IgE. BAT has been applied to the diagnosis of 
allergy to food as well as drug, venom and environmental allergens (52). Its utility seems to 
be best in cases where conventional allergy tests have failed to diagnose allergy and 
provocation tests are to be considered (53). BAT could allow a reduction in the need for 
provocation tests (53). It seems to be valuable also in monitoring patients undergoing 
immuno-modulatory treatments such as allergen-specific immunotherapy (54, 55) and 
omalizumab (56), and in monitoring natural resolution of food allergy (57, 58).  
IgE and IgG4 binding to linear peptides has been studied in food and respiratory allergies. 
IgG4 do not seem to have a role in diagnosing allergies (59). Allergic patients tend to have 
greater IgE binding and broader epitope diversity than tolerant patients (60). Higher epitope 
diversity has also been associated with more severe reactions to food (61). For different 
allergens, immunodominant epitopes have been identified. Technical challenges as well as 
cost-effectiveness, role of tertiary structures and need for validation have hampered its wider 
use in clinical practice (47).  
Other methods such as mediator levels, such as PAF (62, 63), and genetic profiling (64) may 
be useful in predicting patients at risk of developing more severe allergic reactions in the 
future.   
 
Summary and future perspectives 
Over the last decade there have been considerable advances in our understanding of the 
immunological changes underlying clinical allergy and the relationship between skin prick 
and specific IgE test results and clinical manifestations of allergy. We have therefore re-
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considered our approach to interpreting specific IgE test results and how we utilize them in 
clinical practice (Box 2). The meaning of a specific IgE sensitization test results varies 
according to the prevalence of allergy in the test population, a patients’ age, their ethnicity 
and any co-existing clinical diseases such as eczema (Figure 5). The history may also 
indicate that a co-factor must be present for a clinical reaction to occur when a patient with 
specific IgE to the allergen to which they are exposed. We now have data to map specific 
IgE sensitization test results to the probability of clinical allergy for several foods. 
Unfortunately, these do not take into account patient specific factors, neither do the 95% 
positive predictive values that are routinely used in clinical practice.     
The chance of clinical allergy can be more precisely estimated from an IgE sensitization test 
result, by taking into account the presenting features of a patient (pre-test probability). The 
presence of each of these patient specific factors may mean that a patient is more or less 
likely to have clinically allergy with a given test result (Figure 5). Together they may 
considerably modify the interpretation of IgE sensitization test results. We have presented 
two approaches to including pre-test probabilities in the interpretation of results. The 
nomogram approach employs likelihood ratios for specific test results to translate pre-test 
probabilities into the chance of clinical allergy (post-test probability). This approach has not 
been widely implemented, perhaps because of the lack of likelihood ratio data and its 
apparent complexity. Computer based calculator systems can overcome these issues but 
they rely on internal models to generate pre-test probabilities from similar patient 
information, these are limited by a lack of data from a wide range of diverse setting, regions 
and allergens. We need more studies to determine to what extent the meaning of test results 
differ in different populations. Finally a simpler approach has been proposed where each of 
the presenting history and IgE sensitization test results are divided into three levels of 
likelihood for clinical allergy and these are synthesised in a 3 by 3 table (9). This approach 
has not though been formally validated.  
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It is very apparent that there are gaps in our knowledge about the role of IgE in allergic 
disease and our interpretation of IgE sensitization tests. In IgE-mediated allergy, IgE is 
necessary but not sufficient to elicit an allergic reaction. A better understanding of the 
mechanisms of IgE-mediated allergic disease would help us to interpret false-positive IgE 
levels. This includes tissue factors that may play a role at the effector cell level but also 
patient factors (e.g. ethnicity, co-existing inflammatory diseases) and environmental factors 
(e.g. migration, climate change, cultural characteristics) that can function as a promoter or 
an enhancer of the allergic response.  
Component resolved diagnosis (CRD) represents an important advance in specific IgE 
testing. Clinically the ability to be able to discriminate between binding to potent, more 
relevant allergens and cross-reactive, clinical less relevant allergens is exciting. The 
implementation of the technology is currently limited by the lack of studies that focus on 
whether the CRD approach can improve the diagnostic experience of patients. We also 
await the availability of commercial CRD SPT reagents. For multiplex CRD systems we also 
need to develop better approaches to interpreting IgE sensitization data on over 100 
allergens to avoid over diagnosing clinical allergy. 
Lastly we need better systems and approaches to identify clinical important IgE sensitization. 
The BAT and IgE binding to linear allergen peptides are new diagnostic tests currently in 
development. Many patients have symptoms of IgE-mediated allergy without evidence of 
specific IgE sensitization. This may be due to the absence of the allergens that are driving 
the symptoms in the diagnostic extracts or to local production of allergen-specific IgE in the 
target organ. The utility of tests other than IgE sensitization tests, such as the atopy patch 
test, in the diagnosis of conditions with mixed IgE and non-IgE-mediated pathogenesis, such 
as atopic dermatitis and eosinophilic esophagitis, should also be explored further.  
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Figure 1. Approaches to IgE sensitization testing in a patient with possible allergy 
If multiple testing is undertaken without an allergy-focused history, tests are more likely to 
give false positive results impeding the clinical management of the patient. If an allergy-
focused history is used to choose relevant tests, results are more likely to be clinically 
relevant.  
 
Figure 2. Distribution of skin prick test (SPT) results in a group of 100 hypothetical 
clinic patients investigated for peanut allergy 
Black: SPT ≥ 8mm; grey: SPT 3-7mm, white: SPT < 3mm (reproduced from Roberts 2000 
with permission (29)).  
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Figure 3. Probability of food allergy at different specific IgE values.  
Reproduced from Sampson 2001 with permission (30).  
 
Figure 4. Illustration of the use of pre-test probabilities and likelihood ratios to 
diagnosis clinical allergy. (50) 
A 6 year old boy develops an urticarial rash about an hour after consuming a little of a 
peanut snack bar. On the basis of history alone, there is approximately a 25% chance that 
he is clinically allergic to peanut. He has a 4mm wheal to peanut which has a likelihood ratio 
for clinical allergy of 2.4 (31). From the nomogram, it can be seen that the probability that he 
is clinically allergic to peanuts is around 50%. A peanut challenge would be required to make 
a firm diagnosis. However, if the same child had suffered another similar allergic reaction a 
few weeks later on contact with peanuts, the pre-test probability would increase to around 
80%. With a similar skin prick test result the post-test probability would go up to 90%, a 
reasonably high level of certainty meaning that a challenge would not be indicated.  
 
Figure 5. Conceptual figure to illustrate the proposed approach 
❶ The nature of the clinical history should determine the best IgE sensitization test. ❷ 
Each IgE sensitization test result is associated with a specific probability of clinical allergy as 
shown by the interrupted red arrows. ❸ The exact relationship between test result and 
probability of allergy varies according to internal and external factors which may make 
clinical allergy more or less likely in a potentially additive fashion. ❹ So the likelihood of 
clinical allergy can be determine from the IgE sensitization test result and a knowledge of 
other important patient factors; these precise relationships still need to be established.  
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Table 1. Investigations to consider for different presentations of IgE disease (7) 
Disease Skin prick 
tests (SPT) 
Intradermal 
tests (IDT) 
Atopy patch 
test (ATP) 
Serum 
specific IgE 
Challenge
Acute urticaria (+) - - (+) (+) 
Histaminergic 
angioedema (without 
wheals) 
(+) - - (+) (+) 
Atopic dermatitis + - + + + 
IgE-mediated food 
allergies 
+ - - + + 
Oral allergy syndrome +1 - - + (+) 
Eosinophilic oesophagitis + - (+) + - 
Asthma + - - + (+) 
Rhinitis + - - + (+) 
Conjunctivitis + - - + (+) 
Anaphylaxis + (+) - + (+) 
Venom allergy + + - + (+) 
Drug reactions +/- +/- - +/- (+) 
 
Symbols: +: indicated; (+) consider when symptoms are likely to have been precipitated by 
an allergen or other tests have not provided a clear allergic diagnosis; -: not indicated. 1 Skin 
prick tests using fresh fruits or vegetables require a prick-to-prick technique.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Box 1. Examples of organ-specific effects of immediate hypersensitivity reactions 
Skin 
The relevance of specific IgE sensitization is often unclear in patients with atopic dermatitis 
without a history of associated urticaria closely related to allergen exposure as patients often 
have multiple sensitizations to inhalant and food allergens. Delayed eczematous reactions 
up to 24 hours after exposure to relevant allergens, such as house dust mite, grass pollen or 
cows’ milk, are thought to be due to T-cell activation through allergen binding to specific IgE 
on FcεRI of inflammatory dendritic epidermal cells (IDEC) or Langerhans’ cells by antigen 
focusing. Atopy patch testing maybe used but this has low sensitivity although specificity is 
reasonable.  
Although some acute urticaria is caused by immediate hypersensitivity reactions to foods or 
drugs, the majority of cases appear to relate to acute viral infection (usually of the upper 
respiratory tract) or remain idiopathic. Chronic urticaria, by contrast, is almost never the 
result of specific IgE sensitization even though activation of FcεRI appears to be a key 
pathogenic event in some patients with functional autoantibodies directed against FcεRIα or 
cytophilic IgE. Immunological contact urticaria due to environmental exposures or body fluids 
for example, is probably common but underreported in the community and must be 
distinguished from non-immunological urticaria that appears to be mast cell and IgE-
independent. 
 
Airways 
Acute symptoms of allergic asthma and rhinitis develop after exposure to a number of 
triggers. One trigger is inhalant allergens to which the patient has developed IgE 
sensitization. In the nose, this leads to immediate itching, sneezing, rhinorrhoea and 
congestion whereas the lower airways respond with narrowing, oedema and mucus 
secretion. Chronic changes result from the influx of inflammatory cells, including eosinophils 
and damage to epithelial cells. Upper and lower airway symptoms and / or exacerbations 
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can also occur with other triggers, for example viral respiratory tract infections, cold air or 
pollution.  
 
Digestive tract 
The oral allergy syndrome is characterised by immediate oral mucosal symptoms of itching, 
burning and swelling of the mouth after eating fresh fruits, nuts or vegetables containing pan-
allergens (profilins, pathogenesis related protein-10) that are also present in tree or grass 
pollens to which patients with allergic rhinitis/conjunctivitis have become sensitized. Skin 
prick testing and serum specific IgE assays may be negative due to loss of allergenicity in 
standardized reagents. However, prick-to-prick testing with fresh fruits or vegetables will be 
positive. 
Immediate hypersensitivity (food allergy) reactions in the digestive tract present acutely with 
vomiting, diarrhoea and/or abdominal pain. A chronic pattern of inflammation analogous to 
allergen-induced atopic eczema exacerbations with eosinophilic inflammation has been 
linked with IgE sensitization, especially in eosinophilic oesophagitis, but defining 
sensitizations by skin prick and specific IgE testing is inconsistently predictive of a response 
to specific dietary restrictions. Atopy patch testing is often negative.  
 
Systemic reactions 
Anaphylaxis is an acute severe systemic reaction involving the skin, airways, bowel and 
circulation that often presents with syncope or difficulty with breathing. It is usually caused by 
an allergy to a food, drug or venom. Similar presentations can result from non-allergic 
mechanisms, with iodinated contrast material for example. 
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Box 2. Summary  
Relevance of IgE sensitization to clinical allergy  
• Immediate hypersensitivity (type I) reactions commence with cross-linking of IgE 
receptors by allergen.  
• Specific symptoms of clinical allergy depend on the organ affected.  
• Diseases other than allergy may give rise to allergy type symptoms. 
 
Relevance of patient and environmental factors in interpreting IgE 
sensitization test results 
• IgE sensitization tests perform better in clinic populations than the community as 
the prevalence of symptomatic allergy in a clinic population is higher. 
• The meaning of specific IgE sensitization test results varies by patients’ age, 
ethnicity, presenting features of the putative allergic reaction and co-existing 
clinical diseases such as eczema. 
• The presence of co-factors, such as exercise, may be necessary for contact with 
an allergen to results in an allergic reaction in specific IgE positive patients.   
 
Maximizing the available diagnostic information by treating SPT and specific 
IgE results as continuous measures  
• 95% positive predictive values provide a patient perspective but most patients’ 
result are below these levels and they do not take into account other factors such 
as the presenting history. 
• Probability curves allow the chance of clinical allergy to be estimated from 
different test results but they do not take into account other factors such as the 
presenting history. 
 
Utilizing allergen components to improve our diagnostic approach  
• Component resolved diagnosis (CRD) can discriminate between binding to potent, 
more relevant allergens and cross-reactive, clinical less relevant allergens. 
• Multiplex CRD systems can generate results for over a hundred component 
allergens, specific diagnostic algorithms are required to focus attention on the 
clinically relevant sensitization. 
• As current allergen panels are still inadequate, both in number and in biosimilarity, 
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we still depend on allergen extracts for IgE sensitization testing.  
 
Potential for IgG to confound the result of sIgE assay systems  
• The level of specific IgE may be underestimated in the presence of high levels of 
specific IgG, particularly in assay systems using low amounts of allergen.  
 
Integrating patient, environmental and allergen factors with IgE test results to 
predict the likelihood of clinical allergy 
• The chance of clinical allergy can be more precisely estimated from a test result, 
by taking into account the presenting features of a patient (pre-test probability).  
• A nomogram can be used which employs likelihood ratios for specific test results 
to translate pre-test probabilities to the chance of clinical allergy (post-test 
probability).  
• Computer based calculator systems have been developed to calculate the chance 
of clinical allergy based on the presenting features of a patient and their IgE 
sensitization test result. 
• This approach is currently limited by a lack of data to allow us to derive pre-test 
probabilities for diverse setting, regions and allergens. 
 
IgE sensitization test results from the patient perspective  
• Patients generally see IgE sensitization tests as being synonymous with 
diagnostic allergy tests.  
• The interpretation of the IgE sensitization test result should be explained to the 
patient and then there needs to be a two way discussion about subsequent clinical 
management.  
 
Potential new advances in allergy diagnostics  
• Basophil activation test (BAT) may potentially better reflects the presence of 
clinical allergy than other IgE sensitization tests but further validation is required. 
• Other approaches, such as binding to linear peptides and platelet activating factor, 
still require further developmental work before they can be assessed for their role 
in the clinic. 
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